MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and ...